Eiko LifeSciences has informed the stock exchanges about a regulatory penalty imposed on its promoter group entity by the Securities and Exchange Board of India (SEBI). The disclosure, made under Regulation 30 of SEBI's Listing Obligations and Disclosure Requirements, reveals significant compliance issues within the promoter group structure.

SEBI Penalty Details

The regulatory action centers on M/s. Lenus Finvest Private Limited, a promoter group entity of Eiko LifeSciences. SEBI issued an adjudication order dated January 5, 2026, imposing a monetary penalty for regulatory violations spanning nearly two years.

Nature of Regulatory Violation

The SEBI order addresses alleged non-compliance with Regulation 31 of the Substantial Acquisition of Shares and Takeovers (SAST) Regulations. The specific violation relates to non-disclosure of margin pledge requirements by the concerned Depository Participant during the specified transaction period. This type of violation typically involves inadequate disclosure of pledged securities, which can impact transparency in shareholding patterns and market information.

Financial and Operational Impact

Eiko LifeSciences has explicitly stated that the regulatory penalty will not create any financial burden on the company itself. The penalty amount of ₹1.00 lakh is relatively modest and pertains solely to the promoter group entity's actions rather than the listed company's operations.

Promoter Group Response Strategy

The promoter group entity has indicated its intention to challenge the SEBI adjudication order through available legal channels. M/s. Lenus Finvest Private Limited plans to explore all options to contest the regulatory decision and will take appropriate action in due course. This response suggests the promoter group may dispute either the nature of the violation or the penalty amount imposed.

Regulatory Compliance Framework

The disclosure follows SEBI's Master Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, which mandates comprehensive reporting of regulatory actions affecting listed entities and their associated parties. This transparency requirement ensures that investors and stakeholders remain informed about compliance issues that could potentially affect corporate governance standards, even when the direct financial impact on the listed entity remains minimal.

EIKO Lifesciences Limited has announced an Extra-Ordinary General Meeting (EGM) scheduled for January 7, 2026, at 3:00 PM IST through video conferencing. The meeting will seek shareholder approval for a comprehensive fundraising initiative worth ₹21.86 crores through preferential allotment of securities.

Fundraising Structure and Allocation

The company's Board of Directors, in their meeting held on December 11, 2025, approved a two-pronged fundraising approach comprising warrants and equity shares:

The warrants will be convertible into equity shares within 18 months from the allotment date, with each warrant carrying a face value of ₹10.00 and a premium of ₹45.00.

Strategic Investment Objectives

The primary purpose of the fundraising is strategic acquisition and expansion. The company intends to utilize ₹14.44 crores from the warrant proceeds for acquiring the remaining requisite stake in SSM Formulations Private Limited. Upon completion, EIKO Lifesciences will hold a cumulative 51% equity stake in SSM Formulations, making it a subsidiary.

The strategic acquisition will enable the company to expand its product portfolio, enter new markets, and leverage SSM Formulations' manufacturing capabilities for long-term stakeholder value creation.

Allottee Details and Participation

The preferential issue includes participation from both promoter and non-promoter categories:

Warrant Allottees:

Equity Share Allottees:

Pricing and Regulatory Compliance

The issue price of ₹55.00 per security has been determined based on SEBI ICDR Regulations pricing guidelines. The relevant date for floor price determination is December 8, 2025, being 30 days prior to the EGM date. The pricing represents the higher of:

• 90 trading days VWAP: ₹54.98 per equity share
• 10 trading days VWAP: ₹51.26 per equity share

The company has obtained necessary valuation reports and chartered accountant certificates as required under regulatory frameworks.

Terms and Conditions

Key terms for the warrant issue include:

• Payment Structure: 25% of warrant price payable at allotment, balance 75% upon exercise
• Exercise Period: 18 months from allotment date
• Lock-in Period: As prescribed under SEBI ICDR Regulations
• Conversion: Each warrant convertible into one equity share of ₹10.00 face value
• Lapse Provision: Unexercised warrants will lapse after 18 months, with amounts forfeited

The equity shares and converted shares from warrants will rank pari-passu with existing equity shares in all respects, including dividend and voting rights.

Meeting and Voting Details

The EGM will be conducted through video conferencing, with the cut-off date for voting eligibility set as January 2, 2026. Remote e-voting will commence on January 4, 2026, at 9:00 AM and conclude on January 6, 2026, at 5:00 PM. The company has appointed Shravan Gupta, Practicing Company Secretary, as the scrutinizer for the voting process.

Shareholders can access the complete notice and related documents on the company's website at www.eikolifesciences.com and the registrar's portal at https://ivote.bigshareonline.com/landing .